Sanofi

Sanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine k

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under

Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f

After another loss in the US Court of Appeals, Teva will seek a certiorari review by the US Supreme Court of its long-running inhaler patent case against Amneal . Teva had requested a full panel re